Healthcare Active Stocks: Johnson & Johnson (NYSE:JNJ), Endo International (NASDAQ:ENDP), Gilead Sciences (NASDAQ:GILD), Bristol-Myers Squibb (NYSE:BMY)

Johnson & Johnson (NYSE: JNJ) has inked a global licensing deal with the privately held Aduro BioTech for developing new therapies to treat prostate cancer. According to the oncology deal, the private company granted Janssen Biotech, a division of Johnson & Johnson, the exclusive license to certain candidates specifically engineered for the treatment of prostate cancer on the basis of Aduro’s proprietary live-attenuated double-deleted (LADD) … Continue reading Healthcare Active Stocks: Johnson & Johnson (NYSE:JNJ), Endo International (NASDAQ:ENDP), Gilead Sciences (NASDAQ:GILD), Bristol-Myers Squibb (NYSE:BMY)

Healthcare Losers: Bristol-Myers Squibb (NYSE:BMY), LDR Holding Corp (NASDAQ:LDRH), Vanda Pharmaceuticals (NASDAQ:VNDA), Infinity Pharmaceuticals Inc. (NASDAQ:INFI)

Bristol-Myers Squibb Co (NYSE:BMY) and Urban Outfitters (URBN) retreated 6.1 percent and 3.6 percent respectively, after brokers lowered their ratings on these stocks. Weaker-than-expected first-quarter results and dismal second-quarter earnings guidance led Wal-Mart Stores (WMT) to drop 2.4 per cent. Bristol-Myers Squibb Co (NYSE:BMY) stock performance was -6.12% in last session and finished the day at $48.93. Traded volume was 28.56million shares in the last … Continue reading Healthcare Losers: Bristol-Myers Squibb (NYSE:BMY), LDR Holding Corp (NASDAQ:LDRH), Vanda Pharmaceuticals (NASDAQ:VNDA), Infinity Pharmaceuticals Inc. (NASDAQ:INFI)

Zacks restated their neutral rating on shares of Bristol-Myers Squibb Co (NYSE:BMY) in a research note issued to investors on Wednesday. The firm currently has a $52.00 price target on the stock. Bristol-Myers Squibb Co (NYSE:BMY) stock performance was -1.14% in last session and finished the day at $49.52. Traded volume was 8.89million shares in the last session and the average volume of the stock … Continue reading Healthcare Most Active Movers: Bristol-Myers Squibb (NYSE:BMY), Ariad Pharmaceuticals (NASDAQ:ARIA), Avanir Pharmaceuticals (NASDAQ:AVNR), Rexahn Pharmaceuticals (NYSEMKT:RNN)

During the trial, palbociclib — a pill — was combined with the standard anti-estrogen treatment Letrozole. The combined treatment resulted in a 26.1 month progression-free survival rate compared with only 7.5 months for Letrozole alone. Under development by Pfizer Inc. (NYSE:PFE), the medication used in the study is a selective inhibitor of cyclin-dependent kinases (CDK) 4 and 6. Pfizer Inc. (NYSE:PFE) stock performance was -1.06% … Continue reading Healthcare Most Active Stocks: Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Teva Pharmaceutical Industries (NYSE:TEVA), Bristol-Myers Squibb (NYSE:BMY)

Israel-based Teva Pharmaceutical Industries Ltd. (ADR) (NYSE:TEVA) has announced that the U.S. Supreme Court has granted the Company’s Copaxone certiorari petition, and will hear its appeal of a decision from the United States Court of Appeals for the Federal Circuit that invalidated the claim of U.S. Patent 5,800,808. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) stock performance was 1.39% in last session and finished the day … Continue reading Healthcare Active runners: Teva Pharmaceutical Industries (NYSE:TEVA), Bristol-Myers Squibb Co (NYSE:BMY), Merck & Co (NYSE:MRK), Sanofi (NYSE:SNY)

Three years after Pfizer Inc. (NYSE:PFE) announced more than 1,000 layoffs that Gov. Dannel P. Malloy at the time called “terrible news,” the pharmaceutical company and the state said Wednesday they’ve come up with new uses for the Groton site. Malloy and top officials of his administration and Pfizer Inc (NYSE:PFE) said two vacant buildings on the company’s campus will be used for bioscience research … Continue reading Healthcare Active Runners: Pfizer Inc. (NYSE:PFE), Merck & Co. (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), Bristol-Myers Squibb (NYSE:BMY)